Results 161 to 170 of about 2,479 (207)
Some of the next articles are maybe not open access.
Fremanezumab Autoinjector Pen for the Prevention of Migraine
Therapeutic Delivery, 2021Ajovy (fremanezumab, Teva Pharmaceuticals, Israel) is a fully humanized monoclonal antibody that selectively binds both isoforms of the calcitonin gene-related peptide. Calcitonin gene-related peptide is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events in migraine.
openaire +2 more sources
From LBR-101 to Fremanezumab for Migraine
CNS Drugs, 2018Calcitonin gene-related peptide (CGRP) is a neuropeptide of importance in migraine pathogenesis. Its central role in migraine was proven pharmacologically by the development of CGRP receptor antagonists. Monoclonal antibodies targeting CGRP or its receptor are effective in the preventive treatment of episodic and chronic migraine and are considered ...
Marcelo E, Bigal +5 more
openaire +2 more sources
Fremanezumab for the preventive treatment of migraine
Expert Opinion on Biological Therapy, 2019Introduction: The recent approval of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway introduced the first preventive treatments for migraine that were specifically designed to target the underlying pathophysiology of the disease.
Stephen D, Silberstein +2 more
openaire +2 more sources
Fremanezumab for the preventive treatment of migraine in adults
Expert Review of Clinical Pharmacology, 2019Introduction: The Calcitonin Gene-Related Peptide (CGRP) has been implicated in migraine pathophysiology due to its role in neurogenic inflammation and transmission of trigeminovascular nociceptive signal. New molecules targeting CGRP and its receptor have been developed as migraine-specific preventative treatments. Fremanezumab (or TEV-48,125, LBR-101)
Luana Lionetto +2 more
exaly +4 more sources
Fremanezumab-associated injection site alopecia
BMJ Case ReportsCalcitonin gene-related peptide (CGRP) inhibitors, in the form of injectable monoclonal antibodies, are a newer class of drugs for the prevention of migraine headaches. In clinical trials, they have been found to be effective with good tolerance and few adverse effects. Alopecia has been increasingly noted as a post-marketing event associated with CGRP
Mark, Esguerra, Emily Rubenstein, Engel
openaire +2 more sources
Fremanezumab for the prevention of chronic and episodic migraine
Drugs of Today, 2019On September 15, 2018, the U.S. Food and Drug Administration (FDA) approved subcutaneous fremanezumab, a calcitonin gene-related peptide (CGRP) monoclonal antibody, for the treatment of episodic and chronic migraine in adults, with two recommended dosages: 225 mg monthly or 675 mg every 3 months.
L, Lionetto +3 more
openaire +2 more sources
Effectiveness of fremanezumab treatment in patients with migraine headache
Pain MedicineAbstract Objective To evaluate the efficacy and safety of fremanezumab for migraine prevention. Design Retrospective, single-center, real-world study.
Shoji Kikui
exaly +3 more sources